Skyrizi Explained: Psoriasis, PsA & Crohn’s in One Biologic

🌿 Struggling with psoriasis, psoriatic arthritis, or Crohn’s disease? Let’s talk about Skyrizi (risankizumab) — a targeted biologic that’s changing lives with just 4 doses a year after the initial loading phase. Skyrizi is an IL-23 inhibitor, meaning it targets a key source of inflammation in the immune system — without suppressing it entirely. For many patients, that means fewer flares, less joint pain, and clearer skin or improved gut health. 💉 FDA-approved for: ✔️ Moderate-to-severe plaque psoriasis ✔️ Active psoriatic arthritis ✔️ Moderate-to-severe Crohn’s disease ✨ What to expect: – Clear or almost-clear skin for most patients – Reduced joint swelling and morning stiffness – Fewer Crohn’s symptoms and improved quality of life – Convenient quarterly maintenance dosing 📈 Backed by clinical trials. Trusted by dermatologists and rheumatologists. Designed to help you thrive — not just survive. ⚠️ Talk to your doctor about risks like infection or allergic reactions. Regular monitoring may be needed. #Skyrizi #Risankizumab #PsoriasisTreatment #PsoriaticArthritis #CrohnsDisease #Biologics #AutoimmuneDisease #ChronicIllness #ClearSkinGoals #SkyriziJourney #SkyriziResults #Immunology #RheumatologyTok #DermTok #HealthTok #LivingWithPsoriasis #CrohnsWarrior #SpoonieLife #DoctorExplains